Outcomes of dutasteride discontinuation in patients with benign prostatic hypertrophy
-
Published:2022-12-28
Issue:4
Volume:94
Page:521-524
-
ISSN:2282-4197
-
Container-title:Archivio Italiano di Urologia e Andrologia
-
language:
-
Short-container-title:Arch Ital Urol Androl
Author:
Masuda Hiroshi,Mikami Kosuke,Otsuka Kotaro,Hou Kyokusin,Suyama Takahito,Araki Kazuhiro,Kojima Satoko,Naya Yukio
Abstract
To the Editor, Benign prostatic hyperplasia (BPH) is a common cause of lower urinary tract symptoms (LUTS) in elderly males. The current guidelines recommend the use of a 5-alpha reductase inhibitor (5ARI) to treat males with moderate-to-severe LUTS and an enlarged prostate. Combination therapy with an alpha blocker and a 5ARI has proven effective at ameliorating LUTS and reducing the total prostate volume (TPV) and the risk of the disease progression.
Publisher
PAGEPress Publications